Lung Cancer Diagnosis and Staging Using Ultrasound Guidance

This study is currently recruiting participants.
Verified June 2012 by Singapore General Hospital
Sponsor:
Information provided by (Responsible Party):
Mariko Koh, Singapore General Hospital
ClinicalTrials.gov Identifier:
NCT01623765
First received: June 18, 2012
Last updated: June 19, 2012
Last verified: June 2012
  Purpose

To collect data of all patients who have undergone Endobronchial ultrasound for diagnosis or staging of suspected lung cancer


Condition
Lung Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Diagnosis and Staging of Lung Cancer Using Minimally Invasive Technique With Ultrasound Guidance

Resource links provided by NLM:


Further study details as provided by Singapore General Hospital:

Estimated Enrollment: 1000
Study Start Date: January 2010
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Detailed Description:

Introduction: Endobronchial Ultrasound (EBUS) is a procedure that is performed via flexible bronchoscopy under moderate sedation for visualization of lymph nodes in the chest and biopsy under real-time guidance for the staging of lung cancer or evaluation of enlarged lymph nodes. In addition, lung lesions or masses can be visualized and biopsied in the same sitting. The use of EBUS has enhanced the safety and diagnostic yield of flexible bronchoscopy.

Aim: The data of patients with suspected lung cancer or undiagnosed lymph node enlargement in whom bronchoscopy with EBUS guidance is clinically indicated will be collected prospectively.

Results from EBUS are considered positive if a specific diagnosis is obtained ( eg malignancy) or if lymphocytes are present in the lymph node biopsy, indicating accurate sampling of lymph node. In patients with non-diagnostic EBUS, the results from other procedures will be compared for analysis.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with suspected lung cancer

Criteria

Inclusion Criteria:

  • Patients who have undergone endobronchial ultrasound

Exclusion Criteria: None

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01623765

Contacts
Contact: Mariko Koh, MBBS (65) 63214700 mariko.koh.s.y@sgh.com.sg

Locations
Singapore
Singapore General Hospital Recruiting
Singapore, Singapore, 169608
Sub-Investigator: Anantham Devanand, MBBS         
Sponsors and Collaborators
Singapore General Hospital
  More Information

No publications provided

Responsible Party: Mariko Koh, Principal Investigator, Singapore General Hospital
ClinicalTrials.gov Identifier: NCT01623765     History of Changes
Other Study ID Numbers: 2008/458/B
Study First Received: June 18, 2012
Last Updated: June 19, 2012
Health Authority: Singapore: Domain Specific Review Boards

Keywords provided by Singapore General Hospital:
Endobronchial ultrasound, lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014